Promiscuous Ligands from Experimentally Determined Structures, Binding Conformations, and Protein Family-Dependent Interaction Hotspots

Compound promiscuity is often attributed to nonspecific binding or assay artifacts. On the other hand, it is well-known that many pharmaceutically relevant compounds are capable of engaging multiple targets in vivo, giving rise to polypharmacology. To explore and better understand promiscuous binding characteristics of small molecules, we have searched X-ray structures (and very few qualifying solution structures) for ligands that bind to multiple distantly related or unrelated target proteins. Experimental structures of a given ligand bound to different targets represent high-confidence data for exploring promiscuous binding events. A total of 192 ligands were identified that formed crystallographic complexes with proteins from different families and for which activity data were available. These “multifamily” compounds included endogenous ligands and were often more polar than other bound compounds and active in the submicromolar range. Unexpectedly, many promiscuous ligands displayed conserved or similar binding conformations in different active sites. Others were found to conformationally adjust to binding sites of different architectures. A comprehensive analysis of ligand–target interactions revealed that multifamily ligands frequently formed different interaction hotspots in binding sites, even if their bound conformations were similar, thus providing a rationale for promiscuous binding events at the molecular level of detail. As a part of this work, all multifamily ligands we have identified and associated activity data are made freely available.

[1]  M. Rosini,et al.  Polypharmacology: the rise of multitarget drugs over combination therapies. , 2014, Future medicinal chemistry.

[2]  Fatemeh Atyabi,et al.  Fluorescence properties of several chemotherapy drugs: doxorubicin, paclitaxel and bleomycin. , 2016, Biomedical optics express.

[3]  Jürgen Bajorath,et al.  How Frequently Are Pan-Assay Interference Compounds Active? Large-Scale Analysis of Screening Data Reveals Diverse Activity Profiles, Low Global Hit Frequency, and Many Consistently Inactive Compounds. , 2017, Journal of medicinal chemistry.

[4]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[5]  K. Morikawa,et al.  The nuclear receptor PPARγ individually responds to serotonin‐ and fatty acid‐metabolites , 2010, The EMBO journal.

[6]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[7]  Zukang Feng,et al.  Ligand Depot: a data warehouse for ligands bound to macromolecules , 2004, Bioinform..

[8]  P. Bork,et al.  Systematic identification of proteins that elicit drug side effects , 2013, Molecular systems biology.

[9]  Ping Chen,et al.  Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance , 2016, Molecular Cancer Therapeutics.

[10]  J. Bajorath,et al.  Polypharmacology: challenges and opportunities in drug discovery. , 2014, Journal of medicinal chemistry.

[11]  Mineyuki Mizuguchi,et al.  Structural Insight into the Interactions between Death-Associated Protein Kinase 1 and Natural Flavonoids. , 2015, Journal of medicinal chemistry.

[12]  K. Merz,et al.  The Ecstasy and Agony of Assay Interference Compounds , 2017, J. Chem. Inf. Model..

[13]  Alexander Tropsha,et al.  Phantom PAINS: Problems with the Utility of Alerts for Pan-Assay INterference CompoundS , 2017, J. Chem. Inf. Model..

[14]  A. Pîrnău,et al.  Binding interaction of indomethacin with human serum albumin. , 2008, Journal of pharmaceutical and biomedical analysis.

[15]  Jürgen Bajorath,et al.  Highly Promiscuous Small Molecules from Biological Screening Assays Include Many Pan-Assay Interference Compounds but Also Candidates for Polypharmacology. , 2016, Journal of medicinal chemistry.

[16]  J. Bajorath,et al.  X-ray Structures of Target-Ligand Complexes Containing Compounds with Assay Interference Potential. , 2018, Journal of medicinal chemistry.

[17]  B. Shoichet Screening in a spirit haunted world. , 2006, Drug discovery today.

[18]  John P. Overington,et al.  Structural and Functional View of Polypharmacology , 2016, bioRxiv.

[19]  L. Williams,et al.  Surprising roles of electrostatic interactions in DNA-ligand complexes. , 2003, Biopolymers.

[20]  A. Cavalli,et al.  Multitarget Drug Discovery and Polypharmacology , 2016, ChemMedChem.

[21]  W. Atkins,et al.  A quantitative index of substrate promiscuity. , 2008, Biochemistry.

[22]  Jürgen Bajorath,et al.  Systematic mining of analog series with related core structures in multi-target activity space , 2013, Journal of Computer-Aided Molecular Design.

[23]  Mahesh Hegde,et al.  Quercetin, a Natural Flavonoid Interacts with DNA, Arrests Cell Cycle and Causes Tumor Regression by Activating Mitochondrial Pathway of Apoptosis , 2016, Scientific Reports.

[24]  John P. Overington,et al.  ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..

[25]  J. Skolnick,et al.  Catalytic and substrate promiscuity: distinct multiple chemistries catalysed by the phosphatase domain of receptor protein tyrosine phosphatase. , 2016, The Biochemical journal.

[26]  Dusanka Janezic,et al.  ProBiS-Database: Precalculated Binding Site Similarities and Local Pairwise Alignments of PDB Structures , 2012, J. Chem. Inf. Model..

[27]  S. Olesen,et al.  Acetyl-lysine Binding Site of Bromodomain-Containing Protein 4 (BRD4) Interacts with Diverse Kinase Inhibitors , 2014, ACS chemical biology.

[28]  Renxiao Wang,et al.  Analysis of Ligand-Bound Water Molecules in High-Resolution Crystal Structures of Protein-Ligand Complexes , 2007, J. Chem. Inf. Model..

[29]  Fernanda Borges,et al.  Chromone as a Privileged Scaffold in Drug Discovery: Recent Advances. , 2017, Journal of medicinal chemistry.

[30]  Jürgen Bajorath,et al.  Computational Method for the Systematic Identification of Analog Series and Key Compounds Representing Series and Their Biological Activity Profiles. , 2016, Journal of medicinal chemistry.

[31]  G. Lucas,et al.  Drug Interactions and Antiretroviral Drug Monitoring , 2014, Current HIV/AIDS Reports.

[32]  F. Blanco,et al.  Effect of antiinflammatory drugs on COX-1 and COX-2 activity in human articular chondrocytes. , 1999, The Journal of rheumatology.

[33]  Sujata Sharma,et al.  Simultaneous inhibition of anti‐coagulation and inflammation: crystal structure of phospholipase A2 complexed with indomethacin at 1.4 Å resolution reveals the presence of the new common ligand‐binding site , 2009, Journal of molecular recognition : JMR.

[34]  P. Dorrestein,et al.  Phenotyping drug polypharmacology via eicosanoid profiling of blood[S] , 2015, Journal of Lipid Research.

[35]  Alex M. Clark,et al.  2D Depiction of Protein-Ligand Complexes , 2007, J. Chem. Inf. Model..

[36]  J. Lehár,et al.  Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.

[37]  K. Diederichs,et al.  Transport of drugs by the multidrug transporter AcrB involves an access and a deep binding pocket that are separated by a switch-loop , 2012, Proceedings of the National Academy of Sciences.

[38]  Xu Wang,et al.  A structural mechanism of flavonoids in inhibiting serine proteases. , 2017, Food & function.

[39]  M L Bolognesi,et al.  Polypharmacology in a single drug: multitarget drugs. , 2013, Current medicinal chemistry.

[40]  Jürgen Bajorath,et al.  Design of a Three-Dimensional Multitarget Activity Landscape , 2012, J. Chem. Inf. Model..

[41]  John P. Overington,et al.  Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.

[42]  Cathy H. Wu,et al.  UniProt: the Universal Protein knowledgebase , 2004, Nucleic Acids Res..

[43]  Renxiao Wang,et al.  The PDBbind database: collection of binding affinities for protein-ligand complexes with known three-dimensional structures. , 2004, Journal of medicinal chemistry.

[44]  J. Baell,et al.  New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. , 2010, Journal of medicinal chemistry.

[45]  J Willem M Nissink,et al.  Seven Year Itch: Pan-Assay Interference Compounds (PAINS) in 2017—Utility and Limitations , 2017, ACS chemical biology.

[46]  B. Shilton,et al.  Binding of DNA-Intercalating Agents to Oxidized and Reduced Quinone Reductase 2. , 2015, Biochemistry.

[47]  B. Shoichet,et al.  A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. , 2002, Journal of medicinal chemistry.

[48]  L. Wienkers,et al.  Characterization of Ritonavir-Mediated Inactivation of Cytochrome P450 3A4 , 2014, Molecular Pharmacology.

[49]  K. Shokat,et al.  Targeting the cancer kinome through polypharmacology , 2010, Nature Reviews Cancer.

[50]  S. Fetzner,et al.  Quercetin 2,4-Dioxygenase Activates Dioxygen in a Side-On O2-Ni Complex. , 2016, Angewandte Chemie.

[51]  J. Bajorath,et al.  Compound promiscuity: what can we learn from current data? , 2013, Drug discovery today.

[52]  Jürgen Bajorath,et al.  SAR Matrix Method for Large-Scale Analysis of Compound Structure-Activity Relationships and Exploration of Multitarget Activity Spaces. , 2018, Methods in molecular biology.

[53]  R. Morphy,et al.  Designed multiple ligands. An emerging drug discovery paradigm. , 2005, Journal of medicinal chemistry.

[54]  John J. Irwin,et al.  ZINC 15 – Ligand Discovery for Everyone , 2015, J. Chem. Inf. Model..

[55]  Jürgen Bajorath,et al.  X-ray-Structure-Based Identification of Compounds with Activity against Targets from Different Families and Generation of Templates for Multitarget Ligand Design , 2018, ACS omega.

[56]  B. Cronstein,et al.  Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis , 2005, Pharmacological Reviews.

[57]  A. Hopkins Network pharmacology: the next paradigm in drug discovery. , 2008, Nature chemical biology.

[58]  J. Baell,et al.  Chemistry: Chemical con artists foil drug discovery , 2014, Nature.

[59]  B. Giardina,et al.  New developments in anthracycline-induced cardiotoxicity. , 2009, Current medicinal chemistry.

[60]  Michael Schroeder,et al.  Drug Promiscuity in PDB: Protein Binding Site Similarity Is Key , 2013, PloS one.